Making a difference: Molecules, mechanisms and more
Update: 2025-11-17
Share
Description
Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
Comments
In Channel



